Mepolizumab study for asthma or EGPA
Treatments studied
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial tests how well mepolizumab works for people with asthma or a related condition called EGPA, and looks for markers in the blood that may predict organ damage or treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a current diagnosis of asthma or EGPA (a type of blood vessel inflammation).
- Your doctor must have decided to start you on mepolizumab for your condition.
- You have been using a medium to high dose of inhaled steroids plus another asthma controller for at least 6 months.
- If you take steroid pills (like prednisone), your dose has been stable for the last 4 weeks.
- You are 18 years or older.
- You are not pregnant or breastfeeding, and you are not currently using other biologic treatments for asthma.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at inflammation in the ear, nose, and throat area in people with different conditions, including nasal polyps, severe asthma, eGPA (a rare blood vessel disease), and GPA (another rare disease). It compares them to healthy volunteers to better understand what causes local inflammation.
This study tests if adding a new injectable medicine (benralizumab) to your current medium-dose inhaler works better than simply increasing your inhaler dose to control hard-to-treat asthma. It may help people with a specific type of asthma linked to high eosinophil levels.
This study looks at blood and other measures (biomarkers) to understand how well mepolizumab helps people with nasal polyps, with or without asthma. It aims to find response clues that could help personalize treatment in the future.
This study tests a medication called mepolizumab (given as an injection) in people with COPD who have high eosinophils and frequent flare-ups. The goal is to see if it reduces inflammation and helps them breathe better, by looking at airway changes with special scans.
This trial studies whether mepolizumab can reduce ongoing or returning asthma flare-ups in people with severe asthma. If you have severe asthma that still keeps flaring, this may help by targeting a specific inflammation pathway involved in some asthma cases.
This trial tests reslizumab, a medicine that targets a specific immune signal, to improve symptoms in people with eosinophilic granulomatosis with polyangiitis (EGPA). It may help lower disease activity and reduce inflammation-related problems.
Hear when a new Severe Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.